{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:30:53Z","timestamp":1793946653821,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00345524"],"award-info":[{"award-number":["RS-2024-00345524"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.diabres.2026.113281","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:31:53Z","timestamp":1777271513000},"page":"113281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiovascular outcomes with thiazolidinediones and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus undergoing peripheral artery revascularization"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-5146","authenticated-orcid":false,"given":"Ji Woong","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-3914","authenticated-orcid":false,"given":"Jimin","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonsang","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoul","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-7995","authenticated-orcid":false,"given":"Seok-Jae","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Kyu","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-9736","authenticated-orcid":false,"given":"Jinkwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113281_b0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s13300-024-01606-6","article-title":"Epidemiology and burden of peripheral artery disease in people with type 2 diabetes: a systematic literature review","volume":"15","author":"Verma","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113281_b0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","article-title":"Impact of peripheral arterial disease in patients with diabetes\u2013results from PROactive (PROactive 11)","volume":"202","author":"Dormandy","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2026.113281_b0015","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.2337\/dc16-0588","article-title":"Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes","volume":"39","author":"Mohammedi","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113281_b0020","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee 9","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113281_b0025","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4093\/dmj.2022.0372","article-title":"Oldies but goodies: thiazolidinedione as an insulin sensitizer with cardioprotection","volume":"46","author":"Cho","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113281_b0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar","year":"2003","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2026.113281_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112050","article-title":"A critical review on SGLT2 inhibitors for diabetes mellitus, renal health, and cardiovascular conditions","volume":"221","author":"Kumar","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113281_b0040","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 Inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review","volume":"15","author":"Seidu","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113281_b0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hfc.2022.03.001","article-title":"SGLT2 inhibitors and peripheral vascular events: a review of the literature","volume":"18","author":"Marchiori","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.diabres.2026.113281_b0050","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabres.2026.113281_b0055","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","article-title":"An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors","volume":"18","author":"Lamos","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabres.2026.113281_b0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113281_b0065","doi-asserted-by":"crossref","DOI":"10.4178\/epih\/e2014008","article-title":"A guide for the utilization of health insurance review and assessment service national patient samples","volume":"36","author":"Kim","year":"2014","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.diabres.2026.113281_b0070","doi-asserted-by":"crossref","DOI":"10.2196\/34908","article-title":"Incidence and prevalence of peripheral arterial disease in South Korea: retrospective analysis of national claims data","volume":"8","author":"Ryu","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.diabres.2026.113281_b0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4093\/dmj.2024.0780","article-title":"Big data research for diabetes-related diseases using the Korean national health information database","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113281_b0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4070\/kcj.2020.0171","article-title":"Cardiovascular research using the Korean national health information database","volume":"50","author":"Choi","year":"2020","journal-title":"Korean Circ J"},{"key":"10.1016\/j.diabres.2026.113281_b0085","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1161\/STROKEAHA.117.018140","article-title":"Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke","volume":"48","author":"Kim","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.diabres.2026.113281_b0090","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/heartjnl-2017-312930","article-title":"Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015","volume":"104","author":"Kim","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.diabres.2026.113281_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12933-024-02422-9","article-title":"Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT","volume":"23","author":"Ku","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113281_b0100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037950","article-title":"Thiazolidinedione use and cardiovascular outcomes in patients with type 2 diabetes who underwent carotid artery revascularization","volume":"14","author":"Kim","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"1471\u20138","key":"10.1016\/j.diabres.2026.113281_b0105","first-page":"e3","article-title":"Impact of guideline-directed medical therapy on 5-year mortality in patients with newly diagnosed peripheral artery disease","volume":"78","author":"Lee","year":"2023","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.diabres.2026.113281_b0110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3803\/EnM.2024.2266","article-title":"The severity of diabetes and the risk of diabetic foot amputation: a national cohort study","volume":"40","author":"Yu","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabres.2026.113281_b0115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1186\/s12877-022-03686-0","article-title":"Health disparity and healthcare utilization inequity among older adults living in poverty in South Korea: a cross-sectional study","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.diabres.2026.113281_b0120","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2337\/diacare.27.12.2843","article-title":"Peripheral arterial disease, diabetes, and mortality","volume":"27","author":"Leibson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113281_b0125","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14780","article-title":"Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"39","author":"Sim","year":"2022","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2026.113281_b0130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4093\/dmj.2025.0469","article-title":"2025 clinical practice guidelines for diabetes management in Korea: recommendation of the Korean Diabetes Association","volume":"49","author":"Kang","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113281_b0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-021-01266-x","article-title":"Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients","volume":"20","author":"Xiang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113281_b0140","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113281_b0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113281_b0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113281_b0155","doi-asserted-by":"crossref","DOI":"10.1097\/FJC.0000000000001703","article-title":"Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease","author":"Galli","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.diabres.2026.113281_b0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113281_b0165","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113281_b0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor's Choice \u2013 European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication","volume":"67","author":"Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.diabres.2026.113281_b0175","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jdiacomp.2006.03.006","article-title":"The cardiovascular effects of the thiazolidinediones: a review of the clinical data","volume":"21","author":"Kelly","year":"2007","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2026.113281_b0180","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.bjp.0707452","article-title":"Thiazolidinediones: effects on insulin resistance and the cardiovascular system","volume":"153","author":"Quinn","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabres.2026.113281_b0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1475-2840-6-33","article-title":"Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions","volume":"6","author":"Little","year":"2007","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113281_b0190","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jdiacomp.2005.08.003","article-title":"The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells","volume":"20","author":"Goya","year":"2006","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2026.113281_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1043406","article-title":"Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: a systematic review and meta-analysis","volume":"9","author":"Xue","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabres.2026.113281_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.2040-1124.2011.00182.x","article-title":"Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor gamma is a potential target for diabetic macrovascular complications","volume":"3","author":"Matsumura","year":"2012","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2026.113281_b0205","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.101.11.1311","article-title":"Expression and function of PPARgamma in rat and human vascular smooth muscle cells","volume":"101","author":"Law","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113281_b0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.ATV.21.2.201","article-title":"Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling","volume":"21","author":"Kawashima","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2026.113281_b0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bcp.2011.04.004","article-title":"PPAR-gamma and AMPK\u2013advantageous targets for myocardial ischemia\/reperfusion therapy","volume":"82","author":"Morrison","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.diabres.2026.113281_b0220","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1161\/ATVBAHA.112.253823","article-title":"Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia","volume":"32","author":"Nagahama","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2026.113281_b0225","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113281_b0230","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113281_b0235","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.2337\/dc12-2265","article-title":"Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"36","author":"Althouse","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113281_b0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.08.031","article-title":"Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound","volume":"138","author":"Nakayama","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabres.2026.113281_b0245","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcin.2009.04.007","article-title":"A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)","volume":"2","author":"Takagi","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.diabres.2026.113281_b0250","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","article-title":"Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study","volume":"111","author":"Langenfeld","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113281_b0255","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2026.113281_b0260","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jcmg.2011.08.007","article-title":"Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET\/CT imaging study of carotid artery and ascending aorta","volume":"4","author":"Mizoguchi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.diabres.2026.113281_b0265","article-title":"Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study","volume":"36","author":"Narasaki","year":"2024","journal-title":"Lancet Reg Health Am"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:00:04Z","timestamp":1793944804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"alternative-id":["S0168822726002019"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113281","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular outcomes with thiazolidinediones and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus undergoing peripheral artery revascularization","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113281"}}